1. Lue TF，Giuliano F，Montorsi F，et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med，2004，1（1）：6-23.

2. 李柳骥，严季澜. 阳痿病名源流与定义探讨. 北京中医药，2011，（8）：592-594.

3. 中华人民共和国国家标准中医临床诊疗术语（疾病部分 10.19）GB/T 16751.1-1997.

4. Feldman HA，Goldstein I，Hatzichristou DG，Krane et al. Impotence and its medical and psychosocial correlates：results of the Massachusetts Male Aging Study. J Urol，1994，151（1）：54-61.

5. 刘德风，姜辉，洪锴，等. 近5年来中国11个城市门诊勃起功能障碍患者的流行病学变化. 中华男科学杂志，2009，（8）：724-726.

6. 冷静，黄旭元，韩银发，戴继灿. 上海市1582例中老年男子勃起功能障碍流行病学调查. 中国男科学杂志，2000，（1）：29-31.

7. 张庆江，许清泉. 三城市2226例男性勃起功能流行病学调查. 中国男科学杂志，2003，（03）：191-193.

8. 张志超，刘永胜，辛钟成. 北京市社区已婚男子勃起功能障碍患病情况调查. 中华泌尿外科杂志，2003，（12）：63-65.

9. 邵强，孙少鹏，BPC-BPH研究小组. 北京市社区中老年男性性功能调查报告：BPC-BPH研究结果. 中华泌尿外科杂志，2010，31（4）：234-237.

10. 邱智，刘保兴，李宏军，等. 北京地区老年男性性生活现状初步调查. 中华男科学杂志，2010，（3）：223-226.

11. Hamdan FB，Al-Matubsi H Y. Assessment of erectile dysfunction in diabetic patients. Intern J Androl，2009，32（2）：176-185.

12. Bocchio M，Pelliccione F，Mihalca R，et al. Treatment of erectile dysfunction reduces psychological distress. Intern Androl，2009，32（1）：74-80.

13. Cocco G. Erectile dysfunction after therapy with metoprolol：the Hawthorne effect. Cardiology，2009，112（3）：174-177.

14. Khosravj J，Diamandi A，Mistry J，et al. Insulin-like growth factor I（IGF-I）and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab，2001，86（2）：694-699.

15. 王涛，刘波，吴志坚，等. 心理性勃起功能障碍的下丘脑PET研究. 中华男科学杂志，2008，14（7）：602-605.

16. Ucok A，Incesu C，Aker T，et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry，2007，22（5）：328-333.

17. Teusch L，Scherbaum N，Bohme H，et al. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadonesubstituted opiate addicts. Pharmacopsychiatry，1995，28 （3）：84-92.

18. Bacon CG，Hu FB，Giovannucci E，et al. Association of type and duration of diabetes with erectile dysfunction in alarge cohoa of men. Diabetes Care，2002，25：1458-1465.

19. 贺占举，金杰，张凯. 血脂异常与勃起功能障碍. 中国性科学，2009，18（2）：6-11.

20. Tanner FC，Noll G，Boulanger CM，et al. Oxidised low density lipop roteins inhibit relaxations of porcine coronary arteries. Circulation，1991，83：2012-2120.

21. Rosenfeld ME. Oxidised LDL affects multiple atherogenic cellular responses. Circulation，1991，83：2137-2140.

22. Kugiyama K，Kerns SA，Morrisett JD，et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modied low -density lipoproteins. Nature，1990，344：160-162.

23. Smith AD. Psychologic factors in the multidisciplinary evaluation and treatment of erectile dysfunction. Urol Clin North Am，1988，15（1）：41-51.

24. El-Sakka AI，Morsy AM，Fagih BI，et al. Coronary artery risk factors in patients with erectile dysfunction. J Urol，2004，172：251-254.

25. Lewis RW，Puyau FA，Bell DP. Another surgical approach for vasculogenic impotence. J Urol，1986，136 （6）：1210-1212.

26. Lue TF，Hricak H，Schmidt RA，et al. Functional evaluation of penile veins by cavernosography in papaverine-induced erection. J Urol，1986，135（3）：479-482.

27. Chung WS，Shim BS，Park YY. Hemodynamic insult by vascular risk factors and pharmacologic erection in men with erectile dysfunction：Doppler sonography study. World J Urol，2000，18（4）：427-430.

28. 蒲春林，张杰，闵立贵，等. 原发性精索静脉曲张与阴茎勃起功能障碍的相关性探讨. 国际泌尿系统杂志，2011，3l（1）：27-28.

29. Shin HW，Rha YC，Hart DH，et al. Erectile dysfunction and disease-specific quality of life in patients with obstructive sleep apnea.Int J Impot Res，2008，20（6）：549-553.

30. 赵如青. 输精管绝育术后阴茎勃起功能障碍观察.广东医学，2007，28（7）：1125-1126.

31. Segraves R T. Female sexual disorders：psychiatric aspects. Can J Psychiatry，2002，47（5）：419-425.

32. Carrier S，Brock G，Kour NW，et al Pathophysiology of erectile dysfunction. Urology，1993，42：468-481.

33. Wein，Alan J，Kavoussi，Louis R，Novick，Andrew C，et al，Eds Campbell-Walsh Urology（9th Edition）Volume 1：835-837. Saunders，Philadelphia，USA. 2006.

34. Davis-Joseph B，Tiefer L，Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology，1995，45（3）：498-502.

35. Hatzichristou D，Hatzimouratidis K，Bekas M，et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol，2002，168（2）：615-620.

36. Rosen RC，Riley A，Wagner G，et al. The international index of erectile function（IIEF）：a multidimensional scale for assessment of erectile dysfunction. Urology，1997，49（6）：822-830.

37. 朱积川. 男子勃起功能障碍诊治指南. 中国男科学杂志，2004，（1）：68-72.

38. Goldstein I，Lue TF，Padma-Nathan H，et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med，1998，338（20）：1397-1404.

39. Hatzimouratidis K，Amar E，Eardley I，et al. Guidelines on male sexual dysfunction：erectile dysfunction and premature ejaculation. Eur Urol，2010，57（5）：804-814.

40. Laumann EO，Paik A，Rosen RC. The epidemiology of erectile dysfunction：results from the National Health and Social Life Survey. Int J Impot Res，1999，11（Suppl 1）：S60-S64.

41. Hatzichristou DG，Hatzimouratidis K，Ioannides E，et al. Nocturnal penile tumescence and rigidity monitoring in young potent volunteers：reproducibility，evaluation criteria and the effect of sexual intercourse J Urol，1998，159（6）：1921-1926.

42. Morales A，Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am，2001，28（2）：279-288.

43. Lue TF，Giuliano F，Montorsi F，et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med，2004，1（1）：6-23.

44. 张凯，全面康复：勃起功能障碍治疗的新目标. 中华男科学杂志，2006，12（9）：832-835.

45. NIH Consensus Development Panel on Impotence. JAMA，1993，270：83-90.

46. Mulhall J，Althof SE，Brock GB，et al. Erectile dysfunction：monitoring response to treatment in clinical practice：recommendations of an international study panel. J Sex Med，2007，4（2）：448-464.

47. Hatzichristou D，Rosen RC，Broderick G，et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med，2004，1（1）：49-57.

48. Chan SS，Leung DY，Abdullah AS et al. Smokingcessation and adherence intervention among Chinese patients with erectile dysfunction. Am J Prev Med，2010，39（3）：251-258.

49. Harte CB，Meston CM. Association between smoking cessation and sexual health in men. BJU Int，2011 Aug 23［ Epub ahead of print］.

50. Cheng JY，Ng EM，Ko JS，Chen RY. Physical activity and erectile dysfunction：meta-analysis of populationbased studies. Int J Impot Res，2007，19（3）：245-252.

51. Kratzik CW，Lackner JE，M rk I，et al. How much physical activity is needed to maintain erectile function？Results of the Androx Vienna Municipality Study. Eur Urol，2009，55（2）：509-516.

52. Koskim ki J，Shiri R，Tammela T，et al. Regular intercourse protects against erectile dysfunction：Tampere Aging Male Urologic Study. Am J Med，2008，121（7）：592-596.

53. Ma Y，Qin H. Regular and frequent sexual intercourse for elderly men could preserve erectile function. Med Hypotheses，2009，72（3）：370.

54. 郭应禄，朱积川，潘天明等. 口服西地那非治疗勃起功能障碍疗效和安全性的临床研究，中华泌尿外科杂志，2001，22（7）：389-394.

55. Meldrum DR，Gambone JC，Morris MA，Meldrum DA，Esposito K，Ignarro LJ. The link between erectile and cardiovascular health：the canary in the coal mine. Am J Cardiol，2011，108（4）：599-606.

56. Wing RR，Rosen RC，Fava JL，Bahnson J，Brancati F，Gendrano Iii IN，Kitabchi A，Schneider SH，Wadden TA. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med，2010，7（1 Pt 1）：156-165.

57. Hannan JL，Maio MT，Komolova M，et ai. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med，2009，6（Suppl 3）：254-261.

58. Esposito K，Ciotola M，Giugliano F，et al. Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med，2009，6（1）：243-250.

59. Esposito K，Giugliano F，Di Palo C，et al. Effect of lifestyle changes on erectile dysfunction in obese men：a randomized controlled trial. JAMA，2004，291（24）：2978-2984.

60. Esposito K，Giugliano F，Maiorino MI，et al. Dietary factors，Mediterranean diet and erectile dysfunction. J Sex Med，2010，7（7）：2338-2345.

61. Bacon CG，Mittleman MA，Kawachi I，et al. Sexual function in men older than 50 years of age：results from the health professionals’ follow-up study. Ann Intern Med，2003，139（3）：161-168.

62. Jackson G，Montorsi P，Adams MA，et al. Cardiovascular aspects of sexual medicine. J Sex Med，2010，7（4 Pt 2）：1608-1626.

63. Jackson G，Boon N，Eardley I，et al. Erectile dysfunction and coronary artery disease prediction：evidence-based guidance and consensus. Int J Clin Pract，2010，64（7）：848-857.

64. Greenstein A，Mabjeesh NJ，Sofer M，et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed？J Urol，2005，173（2）：530-532.

65. Schwartz EJ，Wong P，Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol，2004，171（2 Pt 4）：771-774.

66. Ayyathurai R，Manoharan M，Nieder AM，et al. Factors affecting erectile function after radical retropubic prostatectomy：results from 1620 consecutive patients. BJU Int，2008，101（7）：833-836.

67. Sand MS，Fisher W，Rosen R，et al. Erectile dysfunction and constructs of masculinity and quality of life in the multinational Men’s Attitudes to Life Events and Sexuality（MALES）study. J Sex Med，2008，5（3）：583-594.

68. Konstantinos H，Edouard A，Ian E，et al. Guidelines on male sexual dysfunction：erectile dysfunction and premature ejaculation. Eur Urol，2010，57：804-814.

69. Tom FL. Campbell-Walsh Urology. 9th ed. Philadlphia：Saunders，2007. 755-760.

70. Arthur L BT，Travis DS，Bruce JT，et al. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafilin type 2 diabetic men with erectile dysfunction. J Urol，2009，181：245-251.

71. Giuseppe MCR，Antonio A，Cristiana V，et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol，2005，47：214-222.

72. Monica GF，Hugo HD，Istvan K，et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology，2006，68：429-435.

73. Goldstein I，Tom FT，Padma NH，et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med，1998，338：1397-1404.

74. Brock GB，Mcmahon CG，Chen KK，et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction：results of integrated analyses. J Urol，2002，168：1332-1336.

75. Hellstrom WJ，Gittelman M，Karlin G，et al.Vardennafil Study Group. Sustained efficacy and tolerability of vardenafil，a highly potent selective phosphodiesterase type 5 inhibitor，in men with erectiledysfunction：results of a randomized，double-blind，26-week placebocontrolled pivotal. Urology，2003，61：8-14.

76. Sommer F，Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol，2005，23：385-392.

77. Porst H，Rajfer J，Casab A，et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med，2008，5：2160-2169.

78. Zumb J，Porst H，Sommer F，et al. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction：findings of the RESTORE study. Eur Urol，2008，54：204-210.

79. Mirone V，Costa P，Damber JE，et al. An evaluation of an alternative dosing regimen with tadalafil，3 times/ week，for men with erectile dysfunction：SURE study in 14 European countries. Eur Urol，2005，47：846-854.

80. Kloner RA. Novel phosphodiesterase type 5 inhibitors：assessing hemodynamic effects and safety parameters. Clin Cardiol，2004，27（4 Suppl 1）：I20-5.

81. Thadani U，Smith W，Nash S，et al. The effect of vardenafil，a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction，on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol，2002，40：2006-2012.

82. Vardi Y，Bulus M，Reisner S，et al. Effects of sildenafil citrate（Viagra）on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol，2003，43（5）：544-551.

83. Auerbach SM，Gittelman M，Mazzu A，et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology，2004，64（5）：998-1003.

84. Hatzichristou D. Phosphodiesterase5 inhibitors and nonarteritic anterior ischemic optic neuropathy（NAION）coincidence or causality？J Sex Med，2005，2：751-758.

85. Purvis K，Muirhead GJ，Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol，2002，53（Suppl 1）：53-60.

86. Wayne JG，Hellstrom，Marc Gittelman，et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg：results of a multicenter，randomized，double-blind，placebo-controlled，9-month study. Eur Urol，2008，53：1058-1065.

87. Jarvi K，Dula E，Drehobl M，et al. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol，2008，179（3）：1060-1065.

88. Padma-Nathan H，McCullough AR，Levine LA，et al. Randomized，double-blind，placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nervesparing radical prostatectomy. Int J Impot Res，2008，20：479-486.

89. Bannowsky A，Schulze H，van der Horst C，et al. Recovery of erectile function after nerve-sparing radical prostatectomy：improvement with nightly lowdose sildenafil. BJU Int，2008，101（10）：1279-1283.

90. McCullough AR，Levine LA，Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate：subanalysis of a longitudinal randomized double-blind placebocontrolled trial. J Sex Med，2008，5：476-484.

91. Montorsi F，Nathan HP，McCullough A，et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy：a randomized，double-blind，placebo controlled trial.J Urol，2004，172（3）：1036-1041.

92. Brock G，Nehra A，Lipshultz LI，et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol，2003，170（4 Pt 1）：1278-1283.

93. Lombardi G，Macchiarella A，Cecconi F，et al. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med，2009，6：1248-1258.

94. Klotz T，Sachse R，Heidrich A，et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients：a RigiScan and pharmacokinetic study. World J Urol，2001，19：32-39.

95. Padma-Nathan H，Stecher VJ，Sweeney M，et al. Minimal time to successful intercourse after sildenafil citrate：results of a randomized，double-blind，placebo-controlled trial. Urology，2003，62（3）：400-403.

96. Rosen RC，Padma-Nathan H，Shabsigh R，et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg：a multicenter，randomized，double-blind，placebocontrolled，at-home study. J Sex Med，2004，1：193-200.

97. Nichols DJ，Muirhead GJ，Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects：absolute bioavailability，food effects and dose proportionality. Br J Clin Pharmacol，2002，53（Suppl 1）：5-12.

98. Rajagopalan P，Mazzu A，Xia C，et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil，an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol，2003，43：260-267.

99. Forgue ST，Patterson BE，Bedding AW，et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol，2006，61：280-288.

100. Hatzichristou D，Moysidis K，Apostolidis A，et al. Sildenafil failures may be due to inadequate patient instructions and follow-up：a study on 100 nonresponders. Eur Urol，2005，47：518-522.

101. Carson CC，Hatzichristou DG，Carrier S，et al. Erectile response with vardenafil in sildenafil nonresponders：a multicentre，double-blind，12-week，flexible-dose，placebo-controlled erectile dysfunction clinical trial. BJU Int，2004，94：1301-1309.

102. Foresta C，Caretta N，Rossato M，et al. Role of androgens in erectile function. J Urol，2004，171（6Pt 1）：2358-2362.

103. FARID SAAD，LOUIS J，et al. A Dose-Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate. J Androl，2008，29：102-105.

104. Mannikarottu AS，Hypolite JA，Zderic SA，et al. Regional alterations in the expression of smooth muscle myosin isoforms in response to partial bladder outlet obstruction. J Urol，2005，173（1）：302-308.

105. Yassin AA. Saad F. Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature. Andrologia，2006，38（1）：34-37.

106. AliaevIu G，Vinarov AZ，Akhvlediani ND. Choice of treatment of erectile dysfunction associated with hypogonadism. Urologia，2010，4：37-8，40-2.

107. Kalinchenko SIu，Vorslov LO，Aglamazian NL，et al. Efficacy and safety of hormonal therapy with androgens（androgel）in men with erectile dysfunction，partial androgen deficiency of aging male and cardiovascular diseases. Urologia，2007，（1）：57，59-61.

108. Corona G，Petrone L，Fisher AD，Mansani R. Sixmonth administration of 1% testosterone gel is able to restore erectile function in hypogonadal patients with erectile dysfunction. Arch Ital Urol Androl，2008，80 （3）：103-108.

109. Saad F，Gooren L，Haider A，et al. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. First international journal of Andrology，2008，40：44-48.

110. EL-Sakka AI，Hassoba HM，Elbakry AM，et al. Prostatic specific antigen in patients with hypogonadism： effect of testosterone replacement. J Sex Med，2005，2（2）：235-240.

111. Isidori AM，Giannetta E，Gianfrilli D，et al. Effects of testosterone on sexual function in men：results of a meta-analysis. Clin Endocrinol（Oxf），2005，63（4）：381-394.

112. AUA Guideline on the Management of Erectile Dysfunction：Diagnosis and Treatment Recommendations. American Urological Association Education and Research，Inc. 2009 Update.

113. 周仲英. 中医内科学. 北京：中国中医药出版社，2003. 276-283.

114. 王琦. 男科学. 河南：河南科学技术出版社，2007. 223-254.

115. 唐汉钧. 中医外科临床研究.北京：人民卫生出版社，2009.408-421.

116. 徐福松. 实用中医男科学.北京：中国中医药出版社，2009.287-308.

117. Levine LA，Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction.Urol Clin North Am，2001，28（2）：335-41，ix-x.

118. Leungwattanakij S，Flynn V Jr，Hellstrom WJ. Intracavernous injection and intraurethral therapy for erectile dysfunction. Urol Clin North Am，2001，28 （2）：343-354.

119. Bechara A，Casab A，Ch liz G，et al. Comparative study of papaverine plus phentolamine versusprostaglandin E1 in erectile dysfunction. J Urol，1997，157（6）：2132-2134.

120. Bennett AH，Carpenter AJ，Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol，1991，146（6）：1564-1565.

121. McMahon CG. A comparison of the response to the intracavernosal injection of papaverine and phentolamine，prostaglandin E1 and a combination of all three agents in the management of impotence. Int J Impot Res，1991，3：113-121.

122. 郭应禄，胡礼泉.男科学. 北京：人民卫生出版社，2004.702-705.

123. 黄宇烽，李宏军. 实用男科学. 北京：科学出版社，2009.492-493.

124. Taneja R. A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone：a pilot study. J Sex Med，2007，4（4 Pt 2）：1136-1141.

125. Fink HA，MacDonald R，Rutks IR，Wilt TJ. Trazodone for erectile dysfunction：a systematic review and meta-analysis. Br J Urol，2003，92：441.

126. Stimmel GL. Gutierrez MA. Pharmacotherapy，2006，26（11）：1608-1615.

127. Lebret T，Herve JM，Gorny P，Worcel M，Botto H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride：a new oral therapy for erectile dysfunction. Eur Urol，2002，41：608.

128. 朱积川. 男子勃起功能障碍诊治指南. 中国男科学杂志，2004，18（1）：68-72.

129. Hatzimouratidis K，Amar E，Eardley I，et al. Guidelines on male sexual dysfunction：erectile dysfunction and premature ejaculation.Eur Urol，2010，57（5）：804-814.

130. Yuan J，Hoang AN，Romero CA，et al. Vacuum therapy in erectile dysfunction-science and clinical evidence. Int J Impot Res，2010，22（4）：211-219.

131. Chen J，Sofer M，Kaver I，et al. Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. J Urol，2004，171 （1）：292-295.

132. Canguven O，Bailen J，Fredriksson W，et al. Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. J Sex Med，2009，6（9）：2561-2567.

133. Raina R，Agarwal A，Allamaneni SS，et al. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology，2005，65（2）：360-364.

134. Dalkin BL，Christopher BA. Preservation of penile length after radical prostatectomy：early intervention with a vacuum erection device. Int J Impot Res，2007，19（5）：501-504.

135. Raina R，Agarwal A，Ausmundson S，et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res，2006，18（1）：77-81.

136. K hler TS，Pedro R，Hendlin K，et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int，2007，100 （4）：858-862.

137. Engel JD. Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol，2011，18（3）：5721-5725.

138. Raina R，Pahlajani G，Agarwal A，et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int，2010，106 （11）：1719-1722.

139. AUA Guideline on the Management of Erectile Dysfunction：An Update. AUA，2009.

140. Wayne JG Hellstrom，DroGo K. montaGue. Sexual Medicine -Sexual dysfunctions in men and women. In：F. Montorsi，R. Basson，G. Adaikan，E. et al. International Consultation on Sexual Dysfunctions. 3th ed Paris，2010.912-910.

141. Shafik A，Shafik I，El Sibai O，et al. Tunica albuginea overlapping：a novel technique for the treatment of erectile dysfunction. Andrologia，2005，37：180-184.

142. Zhang B，Chen J，Xiao H，et al. Treatment of penile deep dorsal venous leakage of erectile dysfunction by embedding the deep dorsal vein of the penis：a single center experience with 17 patients. J Sex Med，2009，6（5）：1467-1473.

143. Siddiqi K，Lewis RW. Surgical therapy for the treatment of erectile dysfunction. Nat Clin Pract Urol，2008，5：174-175.

144. Ang LP，Lim PH. Penile revascularisation for vascular impotence. Singapore Med J，1997，38：285.

145. DePalma RG，Olding M，Yu GW，et al. Vascular interventions for impotence：lessons learned. J Vasc Surg，1995，21：576-585.

146. Grasso M，Lania C，Castelli M，et al. Deepdorsal vein arterialization in vasculogenic impotence：our experience. Arch Ital Urol Nefrol Androl，1992，64 （4）：309-312.

147. Jarow JP，DeFranzo AJ. Long-term results of arterial bypass surgery forimpotence secondary to segmental vascular disease. J Urol，1996，156：982-985.

148. Montorsi F，Deh F，Salonia A，et al. Penile implants in the era of oral drug treatment for erectile dysfunction. BJU Int，2004，94（5）：745-751.

149. Konstantinos Hatzimouratidis，Edouard Amar，Ian Eardley，et al. Guidelines on Male Sexual Dysfunction：Erectile Dysfunction and Premature Ejaculation. European Urology，2010，57：804-814.

150. Wilson SK，Carson CC，Cleves MA，et al. Quantifying risks of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol，1998，159（5）：1537-1540.

151. Bishop JR，Moul JW，Sihelnik SA，et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol，1992，147：386-388.

152. Montague DK，Angermeier KW. Penile prosthesis implantation. Urol Clin North Am，2001，28（2）：355-61，x.

153. Carson CC 3rd. Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants. J Urol，2004，171（4）：1611-1644.

154. Wolter CE，Hellstrom WJ. The hydrophilic-coated inflatable penile prosthesis：1-year experience. J Sex Med，2004，1（2）：221-224.

155. D’Amico DF，Parimbelli P，Ruffolo C. Antibiotic prophylaxis in clean surgery：breast surgery and hernia repair. J Chemother，2001，13：108-111.

156. Zibari GB，Gadallah MF，Landreneau M，et al. Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections. Am J Kidney Dis，1997，30（3）：343-348.

157. Hill C，Flamant R，Mazas F，Evrard J. Prophylactic cefazolin versus placebo in total hip replacement：report of a multicentre double-blind randomised trial. Lancet，1981，1（8224）：795-796.

158. Dos Reis JM，Glina S，Da Silva MF，Furlan V. Penile prosthesis surgery with the patient under local regional anesthesia. J Urol，1993，150（4）：1179-1181.

159. Kaufman JJ. Penile prosthetic surgery under local anesthesia. J Urol，1982，128（6）：1190-1191.

160. Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol，2000，163（2）：481-482.

161. Montorsi F，Rigatti P，Carmignani G，et al. AMS three-piece inflatable implants for erectile dysfunction：a long-term multi-institutional study in 200 consecutive patients. Eur Urol，2000，37（1）：50-55.

162. Goldstein I，Newman L，Baum N，et al. Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol，1997，157（3）：833-839.

163. Wilson SK，Henry GD，Delk JR Jr，et al. The mentor Alpha 1 penile prosthesis with reservoir lock-out valve：effective prevention of autoinflation with improved capability for ectopic reservoir placement. J Urol，2002，168（4 pt1）：1475-1478.

164. Thiel DD，Broderick GA，Bridges M. Utility of magnetic resonance imaging in evaluating inflatable penile prosthesis malfunction and complaints. Int J Impot Res，2003，15（Suppl 5）：S155-S161.

165. Khatana SA，Taveira TH，Miner MM，et al. Does cardiovascular risk reduction alleviates erectile dysfunction in men with type II diabetes mellitus？Int J Impot Res，2008，20（5）：501-506.

166. Schwartz BG，Kloner RA. How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors. Int J Impot Res，2009，21 （6）：327-335.

167. Jackson G. Prevention of cardiovascular disease by the early identification of erectile dysfunction. Int J Impot Res，2008，20（Suppl）2：S9-14.

168. Wespes E，Amar E，Eardley I，et al. Guidelines on male sexual dysfunction：erectile dysfunction and premature ejaculation. European Association of Urology，2009.

169. Esposito K，Giugliano F，Maiorino MI，et al. Dietary factors，Mediterranean diet and erectile dysfunction. J Sex Med，2010，7（7）：2338-2345.

170. Tamler R，Mechanick JI. Dietary supplements and nutraceuticals in the management of andrologic disorders. Endocrinol Metab Clin North Am，2007，36 （2）：533-552.

171. Soner BC，Murat N，Demir O，et al. Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction？Int J Impot Res，2010，22（4）：227-233.

172. Gamidov SI，Mazo EB，Gasanov RV，et al. Prophylactics of erectile dysfunction in patients with metabolic syndrome. Bull Exp Biol Med，2009，148 （2）：318-321.

173. Pohjant hti-Maaroos H，Palom ki A，Hartikainen J. Erectile dysfunction，physical activity and metabolic syndrome：differences in markers of atherosclerosis. BMC Cardiovascular Disorders，2011，11：36-45.

174. Gazzaruso C，Solerte SB，Pujia A，et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease：a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol，2008，51（21）：2040-2044.

175. Lee JC，B nard F，Carrier S，et al. Do men with mild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population？BJU int，2010，107：956-960.

176. Liu DF，Jiang H，Hong K，et al. Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors. Clin Med J，2010，123（22）：3258-3261.

177. Finley DS，Rodriguez E Jr，Skarecky DW，et al. Quantitative and qualitative analysis of the recovery of potency after radical prostatectomy：effect of unilateral vs bilateral nerve sparing. BJU Int，2009，104（10）：1484-1489.

178. Mulhall JP，Parker M，Waters BW，Flanigan R. The timing of penile rehabilitation after bilateral nervesparing radical prostatectomy affects the recovery of erectile function. BJU Int，2010，105（1）：37-41.

179. Padma-Nathan H，McCullough AR，Levine LA，et al. Randomized，double-blind，placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res，2008，20（5）：479-486.

180. Pahlajani G，Raina R，Jones JS，et al. Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function. BJU Int，2010，106（10）：1524-1527.

181. Raina R，Pahlajani G，Agarwal A，et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int，2010，106（11）：1719-1722.